45- Feagan BG, Kozma CM, Slaton TL, Olson WH, Wan GJ. Healthcare costs for Crohn’s disease
patients treated with Infliximab:CD: a propensity weighted comparison of the effects of treat-
ment adherence. J Med Econ. 2014;17(12):872–80. - Carter CT, Waters HC, Smith DB. Impact of infliximab adherence on Crohn’s disease-related
healthcare utilization and inpatient costs. Adv Ther. 2011;28(8):671–83. - Leombruno JP, Nguyen GC, Grootendorst P, Juurlink D, Einarson T. Hospitalization and sur-
gical rates in patients with Crohn’s disease treated with Infliximab:CD: a matched analysis.
Pharmacoepidemiol Drug Saf. 2011;20(8):838–48. - Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care
utilization and costs by Crohn’s disease patients. Adv Ther. 2009;26(10):936–46. - Wan GJ, Kozma CM, Slaton TL, Olson WH, Feagan BG. Inflammatory bowel disease: health-
care costs for patients who are adherent or non-adherent with infliximab therapy. J Med Econ.
2014;17(6):384–93. - D’Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscopic
and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s dis-
ease: a European multicenter trial. Gastroenterology. 1999;116(5):1029–34. - Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, et al. Scheduled main-
tenance treatment with infliximab is superior to episodic treatment for the healing of mucosal
ulceration associated with Crohn’s disease. Gastrointest Endosc. 2006;63(3):433–42; quiz 64. - Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al.
Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med.
1999;340(18):1398–405. - Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab
maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350(9):876–85. - Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces
hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology.
2005;128(4):862–9. - Topstad DR, Panaccione R, Heine JA, Johnson DR, MacLean AR, Buie WD. Combined
seton placement, infliximab infusion, and maintenance immunosuppressives improve healing
rate in fistulizing anorectal Crohn’s disease: a single center experience. Dis Colon Rectum.
2003;46(5):577–83. - Sands BE, Blank MA, Patel K, van Deventer SJ. Long-term treatment of rectovaginal fistu-
las in Crohn’s disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol
Hepatol. 2004;2(10):912–20. - Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F. Treatment of perianal fistulas in Crohn’s
disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response
in selected cases: a pilot study. Scand J Gastroenterol. 2006;41(9):1064–72. - Yarur A, Kanagala V, Stein D, Czul F, Agrawal D, Zadvornova Y, et al. 514 Higher inflix-
imab trough levels are associated with a higher rate of perianal fistula healing in patients with
Crohn’s disease. Gastroenterology. 2016;150(4):S105–S6. - Baert F, Noman M, Vermeire S, Van Assche G, D’Haens G, Carbonez A, et al. Influence of
immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med.
2003;348(7):601–8. - Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and man-
agement of infusion reactions to Infliximab:CD: a large center experience. Am J Gastroenterol.
2003;98(6):1315–24. - Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human
anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the
CLASSIC-I trial. Gastroenterology. 2006;130(2):323–33; quiz 591. - Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, et al.
Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial.
Gut. 2007;56(9):1232–9.
3 Antitumor Necrosis Factor Agents in Crohn’s Disease